February 19, 2009

Pharma Patent Case Study

Generics’ envy, Patent owner’s pride: Roche’s 'Valcyte' triumphs at the Chennai Patent Office

Dear All,

On January 1, 2005, the product patent regime in India was born again. In these few years of product patent regime, the Indian pharmaceutical industry has witnessed some tough battles in Indian courts and the four Patent Offices, between MNC patent holders and Indian generic drug manufacturers.

Roche’s drug “Valcyte” (Valganciclovir hydrochloride) too has faced legal challenges. It met its pre-grant stage challenge in which it recently tasted victory at Chennai Patent Office, and is now facing post grant challenge. Roche has instituted infringement action against Cipla and is awaiting its hearing.

Please click here for the document tracing the journey of Valcyte in India and the hurdles it has met and will meet to survive as a valid patent in India.

IP-Pharma Team
Aditi Nadkarni / Gowree Gokhale

You can direct your queries or comments to IP-Pharma Team

 

Welcome to connect with us at interesting conferences, seminars and events (more...) 
 
Nishith Desai Associates (NDA) is a research-based legal & tax counseling law firm. NDA renders transactional and regulatory services to pharma and life science companies worldwide. It is involved in providing legal and strategic advice in mergers and acquisitions, formation of Joint Ventures or new companies in India, private equity Investments and setting up of healthcare funds. It also assists global companies by developing tax, Intellectual Property, litigation and regulatory strategy for their India operations. NDA also assists companies in a range of litigation matters including patent challenges in India. NDA has advised 7 out of the top 20 pharmaceutical companies in the world.
  VIDEO
Nishchal Joshipura on Satyam Maytas deal
Vyapak Desai on FII, FDI norms
Kartik Ganapathy on Ranbaxy Daiichi deal
Nishith Desai on Vodafone Controversy
Siddharth Shah on P Notes
 
  SUBSCRIPTION

We update our clients by sending various hotlines. You can subscribe to one / more hotlines also. You can email us for registering yourself for any of the hotlines given below.
Corpsec Hotline
Tax Hotline
HR Hotline
iCe Hotline
Annual Budget
FII Hotline
Pharma Update
Infra Update
IP Update
Dispute Resolution Hotline

Unsubscribe
Feedback





Disclaimer: The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This hotline provides general information existing at the time of preparation. The hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This hotline does not substitute the need to refer to the original pronouncements. We are not authorized to practice US law and no reliance should be placed on any US law related comments or interpretations.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.
NDA